• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Thought Leader Insight & Analysis Report Anticoagulants Q3 2011 Product Image

Thought Leader Insight & Analysis Report Anticoagulants Q3 2011

  • ID: 2050481
  • August 2011
  • 148 Pages
  • Medpredict

This report reviews the key competitive dynamics taking place in the antiplatelets and antithrombotics (anticoagulants) categories. We interviewed six internationally recognized experts for this panel and bring together their perspectives, opinions and predictions on:

- Burgeoning competition between Pradaxa (dabigatran), Xarelto (rivaroxaban), Eliquis (apixaban) and pipeline competitors Lixiana (edoxaban) and betrixaban; in SPAF, ACS, cancer, VTE/PE, mechanical valves. Formulary considerations / SPAF pharmacoeconomics.

- Competition between Brilinta (ticagrelor), Effient (prasugrel), Plavix (clopidogrel) and pipeline competitors elinogrel, vorapaxar, atopaxar and cangrelor. Formulary considerations.

- Acute and chronic treatment of ACS patients; with antiplatelet +/- antithrombotics.

Executive Summary

Report Highlights
- Antiplatelets
- Antithrombotics / Anticoagulants

Key Findings

- Formulary Considerations
- Plavix (Clopidogrel; Bms)
- Brilinta (Ticagrelor; Astra-Zeneca)
- Effient (Prasugrel; Lilly / Daiichi-Sankyo)
- Elinogrel (Portola / Novartis)
- Vorapaxar (Merck)
- Atopaxar (Eisai)
- Cangrelor (The Medicines Company)

Antithrombotics / Anticoagulants
- Spaf Pharmacoeconomics
- Role Of Antithrombotics In Acs
- Therapeutics
- Pradaxa (Dabigatran; Boehringer-Ingelheim)
- Xarelto (Rivaroxaban; Bayer-Schering / J&J)
- Eliquis (Apixaban; Bristol-Myers Squibb / Pfizer)
- Lixiana (Edoxaban; Daiichi-Sankyo)
- Betrixaban (Portola)
- Fxa Antidote (Portola)
- Lovenox (Enoxaparin; Sanofi-Aventis)
- Otamixaban (Sanofi-Aventis)

Thought-Leader Discussions
- Interview Cv02584
- Interview Cv02585
- Interview Cv02586
- Interview Cv02587
- Interview Cv02588
- Interview Cv02589

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos